Welcome to our dedicated page for Quantumzyme Ord Shs SEC filings (Ticker: QTZM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quantumzyme Corp (QTZM) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current and historical reports filed with the U.S. Securities and Exchange Commission. Quantumzyme Corp, a Nevada corporation, uses these filings to report material events, corporate actions, and governance changes to the market.
Among the key documents is an 8-K filing in which the company describes Board and majority stockholder approval of an amendment to its Articles of Incorporation to change its name from Quantumzyme Corp to Quantum Genesis AI Corp. The filing explains the steps required for this change, including completion of a Schedule 14C information statement process, a 20-day waiting period under federal securities laws, and the subsequent filing of a Certificate of Amendment with the Nevada Secretary of State.
These filings also outline how the name change is expected to affect the company’s securities. The 8-K states that shareholder rights, authorized capital, issued and outstanding shares, CUSIP number, and par value will remain unchanged, and notes that a new ticker symbol will be assigned by FINRA after it reviews the Issuer Company-Related Action Notification Form submitted by the company.
Stock Titan enhances these SEC documents with AI-powered summaries that highlight the core points of each filing in plain language. Users can quickly see what corporate actions Quantumzyme Corp has reported, how those actions may influence its market identity, and where in the filings specific details are discussed. Real-time updates from EDGAR help ensure that new 8-Ks, proxy-related materials such as Schedule 14C information statements, and other relevant reports for QTZM are available for review as they are filed.
Quantumzyme Corp. has formally changed its corporate name to Quantum Genesis AI Corp. following approval by its board on January 7, 2026 and by the holder of 79.56% of the voting power on November 30, 2025. The company filed a Certificate of Amendment with the Nevada Secretary of State on February 11, 2026, making the name change effective upon filing.
The company’s OTC trading symbol will change to “QGAI”, with the name and symbol change taking effect in the market at the open of business on February 17, 2026, as processed and announced by FINRA on February 13, 2026. These changes do not affect shareholder rights, authorized capital, issued and outstanding shares, par value, or the company’s CUSIP number.
Quantumzyme Corp. is changing its corporate name to Quantum Genesis AI Corp. after approval by the Board and written consent of stockholders holding 31,000,000 shares of common stock, representing approximately 79.565% of the company’s outstanding voting power as of November 30, 2025. No stockholder meeting or proxies are needed because the required majority approved the amendment to the Articles of Incorporation by written consent.
The name change will become effective after a 20-day waiting period following the mailing of this Information Statement and the filing of a Certificate of Amendment with the Nevada Secretary of State. As of the Record Date, 38,962,050 shares of common stock were issued and outstanding. The name change will not affect stockholder rights, the company’s authorized capital, issued and outstanding shares, CUSIP number, or par value, and stockholders do not have dissenters’ or appraisal rights under Nevada law.
Quantumzyme Corp. reported that its board and a majority stockholder approved an amendment to change the company’s name to Quantum Genesis AI Corp. The name change is not yet effective because the amended Articles of Incorporation still must be filed with the Nevada Secretary of State after completion of the Schedule 14C information statement process and the required 20-day waiting period under federal securities laws.
The company has also submitted a company-related action notification to FINRA to reflect the new name and request a new stock symbol. The change will not affect shareholder rights, the company’s authorized capital, issued and outstanding shares, CUSIP number, or par value. A new ticker symbol will be assigned by FINRA once it finishes reviewing the corporate action.
Quantumzyme Corp. reported another pre-revenue quarter for the three months ended October 31, 2025, with no sales and a net loss of $49,868, narrower than the $65,523 loss a year earlier as operating expenses declined.
The balance sheet is extremely weak: cash was just $184 against current liabilities of $490,769, creating a working capital deficit of $490,585 and an accumulated deficit of $5,686,435. Notes payable rose to $268,594, and the company subsequently issued an additional $3,045 promissory note at a 10% interest rate, underscoring its reliance on short-term debt financing.
Management states that these conditions raise “substantial doubt” about the company’s ability to continue as a going concern and notes there are no firm financing agreements in place. The report also discloses material weaknesses in internal controls, including limited staff, lack of segregation of duties, and the absence of an audit committee, although no material legal proceedings are pending and 38,962,050 common shares were outstanding as of December 15, 2025.
Quantumzyme Corp. (QTZM) files an amended Annual Report to update key disclosures. The amendment replaces the prior audit opinion from Fruci & Associates II, PLLC with an updated report that reflects final authorization, and adds $54,500 of stock-based compensation for CEO Naveen Krishnarao Kulkarni to the 2024 executive compensation table.
Quantumzyme is an early-stage enzyme engineering company focused on greener production of pharmaceutical ingredients, initially targeting Ibuprofen manufacturing through licensed biocatalysts rather than in-house production. The company has not yet generated revenue, operates with a single employee, and discloses substantial risks, including dependence on third-party manufacturers, significant competition, going concern uncertainty, and a dual-class capital structure that concentrates voting control. As of November 10, 2025, 38,962,050 common shares were outstanding, and non-affiliate equity value at the prior second fiscal quarter was about $4,327,050.
Quantumzyme Corp. (QTZM) filed its annual report for the year ended July 31, 2025. The company is a development-stage biotransformation business focused on engineered enzymes, with its first product aimed at greener ibuprofen API production. It plans to license the enzyme to manufacturers and pursue royalties while using third-party facilities for scale-up.
Management discloses a going concern risk and the need for additional capital to execute its plan. Governance is concentrated via dual-class preferred stock with 100 and 500 votes per share. The company reports one employee and shared office space costing about $500 per month. As of November 10, 2025, 38,962,050 common shares were outstanding; the aggregate market value of non‑affiliate equity was approximately $4,327,050 as of the last business day of the most recently completed second fiscal quarter. No material cybersecurity incidents were identified. Common stock is registered under Section 12(g); none under Section 12(b).